Search

Search Constraints

You searched for: Author/Creator Masuda, N

Search Results

1. 1200PSerum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer. (23rd October 2018)

3. 151OSingle agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial. (13th May 2019)

4. 184ODistant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial. (23rd October 2018)

5. 361TiPA phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study). (23rd October 2018)

6. 40OBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). (25th November 2018)

7. 42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). (25th November 2018)

10. LBA2_PROverall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. (23rd October 2018)